First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Janssen Research & Development, LLC65 enrolled

Overview

This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetic (the effect of the body on the investigated drug) and signs of clinical efficacy of increasing single doses or four repeated doses of NNC 0142-0002 in patients with rheumatoid arthritis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Inflammation Rheumatoid Arthritis

Interventions

NNC0142-0002DRUG

Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

NNC0142-0002DRUG

Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

NNC0142-0002DRUG

Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Active rheumatoid arthritis, characterized by a Disease Activity Score (DAS28) above 3.2, and a diagnosis of at least three months duration * Aged between 18 and 75 years (both inclusive) * Subjects on stable doses of methotrexate for at least 4 weeks prior to dosing * Use of highly effective contraception during the trial (both males and females) Exclusion Criteria: * A chronic inflammatory autoimmune or joint disease other than RA (rheumatoid arthritis) * An active or latent tuberculosis * Any investigational or experimental therapy within 4 weeks or 5 half-lives (whichever is longer) prior to the screening visit * A known significant cardio-vascular disease * Vaccination against live virus or bacteria within 4 weeks prior to randomization * The use of concomitant medications that are prohibited in the trial (e.g., certain DMARDs (antirheumatic therapies that are disease modifying), biologics (here: biotechnologically produced antibodies), intra-articular corticoid-injections, etc.) * A positive test result for human immunodeficiency virus (HIV) infection, hepatitis B and/or hepatitis C, or tuberculosis skin test * Donation of greater than or equal to 400 ml of blood within 8 weeks prior to trial entry

Locations (1)

Unnamed facility

Berlin, Germany

Outcomes

Primary Outcomes

Frequency of Adverse Events

Adverse event: any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. Serious AE: AE that at any dose level resulted in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalization, a persistent/significant disability/incapacity, a congenital anomaly or birth defect, or an important medical event that may jeopardize the subject and require medical or surgical intervention.

Time frame: Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity.

Secondary Outcomes

Area Under the Concentration-time Curve (AUC)

Systemic exposure to NNC0142-0002.

Time frame: Data were collected from 0 hours to at least Day 43 (SD cohorts) and Day 85 (MD cohorts), and until the receptor occupancy was confirmed below the cut-off level for receptor positivity.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.